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EFFECTS OF GLP-1 AND 2,5-ANHYDRO-D-MANNITOL ON 
INSULIN SECRETION AND PLASMA GLUCOSE IN MICE 
B. Ahren, S. Lindskog, G. van Dijk, A.J.W. Scheurink and A.B. 
Steffens 
Departments of Medicine, Lund University, Malmo, Sweden and Ani- 
mal Physiology, University of Groningen, Haren, The Netherlands 
ABSTRACT 
The truncated glucagon-like peptide- 1 (GLP- 1(7.36,amide or GLP- 1) stimulates 
insulin secretion, enhances glucose elimination and is of potential interest in dia- 
betes treatment. We studied the hypoglycemic action of GLP-l in normal mice 
when given alone or together with the fiuctose analogue, 2,5-anhydro-D-mannitol 
(2,5-AM), which inhibits glycogenolysis and gluconeogenesis. GLP- 1 (32 nmovkg 
iv) lowered plasma glucose levels after 25 min to 4.6kO.2 mmovl compared with 
7.3f0.4 mmoVl in controls (P<O.OOl). Also 2,5-AM (0.5 VmoVkg iv) reduced 
plasma glucose levels, to 5.6kO.3 mmoyl (P<O.Ol). When given together, the 
glucose lowering action of GLP-1 and 2,5-AM was additive, since the 25 min glu- 
cose level was 2.8kO.2 mmoyl. At 5 min after injection, GLP-1 had increased 
plasma insulin levels to 693+68 pmoVl compared with 342f42 pmovl in controls 
(P<O.Ol). 2,5-AM abolished this increase. Furthermore, GLP-I (32 nmokg) did 
not affect the glycogen content, neither in the liver nor in the gastrocnemic muscle 
in samples taken at 30 min after injection. Moreover, in isolated islets incubated at 
3.3 and 8.3 mmol/l glucose, 2,5-AM at 75 mmoyl inhibited glucose-stimulated 
insulin secretion (Pc0.05) showing that 2,s-AM inhibits insulin secretion both in 
vivo and in vitro. We conclude that GLP-1 may reduce plasma glucose levels also 
to levels below the basal levels under normal conditions, and that an insulin- and 























































A H R ~ N  ET AL. 
During recent years, the truncated form of glucagon-like peptide- 1 , GLP-1(7- 
s6pnide, or, as it is called here, GLP-I, has been postulated to be a potential new 
treatment modality for diabetes (1). This suggestion is based on studies showing 
that GLP- 1 stimulates insulin secretion and lowers blood glucose concentrations 
both under normal conditions and in diabetes (1-6). Furthermore, the insulinotropic 
action of GLP-1 is glucose-dependent (7,s) which makes hypoglycemia unlikely to 
evolve following administration of the peptide. This conclusion is supported by our 
previous study which demonstrated that in normal mice, an intravenous injection of 
a high dose of GLP-1 stimulates a short-lived and transient insulin secretion with 
no hypoglycemia during the first 10 min after injection (3). 
However, we have previously also demonstrated that GLP-I enhances the glu- 
cose elimination rate during an intravenous glucose tolerance test both in normal 
and in insulin-deficient alloxan-diabetic mice (9), and, similarly, that the peptide 
increases the insulin sensitivity during a hyperglycemic clamp in patients with in- 
sulin-deficient type 1 diabetes (1). This suggests that GLP-I also might lower the 
blood glucose concentrations by a peripheral, insulin-independent, action. This 
could indicate that GLP-1 would reduce the glycemia also to levels below those 
seen basally and therefore indeed induce hypoglycemia but that this would evolve 
at a later time point than that seen for its insulinotropic action. In this study, we 
have therefore examined the time course of plasma glucose levels after an intrave- 
nous injection of GLP-1 in normoglycemic mice. We have also studied whether the 



















































GLP-1, 2,5-AM AND INSULIN SECRETION 585 
on plasma glucose levels, since 2,5-AIvl has previously been demonstrated to in- 
duce hypoglycemia in mice through inhibiting gluconeogenesis and glycogenolysis 
and thereby hepatic glucose delivery (10). Thus, administration of 2,5-AM would, 
first, preclude any hepatic actions of GLP-1 and, second, the simultaneous use of 
2,5-AM and GLP-1 would allow conclusions on the issue whether GLP-1 could 
induce severe hypoglycemia. To study the possibility that a glycogenic action of 
GLP-1 contributes to its hypoglycemic effect, liver and muscle glycogen content 
were also examined. Furthermore, during the course of this study, we demon- 
strated that insulin secretion in mice was inhibited by 2,5-AM. Therefore, we also 
studied whether such an action is mediated by a direct islet action of the substance 
by examining insulin secretion from isolated mouse islets. 
MATERIALS AND METHODS 
Animals. 
Adult female NMRl mice (Bomholtgird Breeding and Research Centre Ltd, 
Ry, Denmark), weighing 22-25 g, were used. The animals had been kept on a stan- 
dard pellet diet and tap water ad libitum before the experiments. The study was 
approved by the Ethic Committee of the Lund University. 
In vivo exDeriments. 
The mice were anesthetized with thipenthal 1.8 mglanimal injected ip. At 15 
min after the ip injection, synthetic human GLP-1 (Peninsula Laboratories, St 



















































586 AH&N ET AL. 
and 2,5-anhydro-D-mannitol (2,5-AM; Sigma Chemical Co, St Louis, Mo, USA; 
dissolved in saline) were injected intravenously into a tail vein either alone or 
together. Controls were injected with saline. Blood was sampled from the retro- 
bulbar plexus immediately before and at 5,  10, 15, 25 and 35 min after the iv injec- 
tion, and plasma was immediately separated and stored at -20°C until analyses. The 
dose of GLP-1 which was used (32 nmoykg) has previously been shown to maxi- 
mally stimulate insulin secretion in mice (3), and the doses used for 2,5-AM (0.5 
pmoVkg = 75 m a g )  has previously been shown to induce hypoglycemia in mice 
(10). To study whether GLP-1 affects the muscle or liver glycogen content, speci- 
mens from liver and the gastrocnemic muscle were rapidly taken from mice killed 
by cervical dislocation at 30 min after an intravenous injection of GLP-1 (32 
nmolkg) or saline. The tissue was rapidly frozen and stored at -20°C. 
In vitro exDeriments. 
Islets were isolated by the collagenase digestion technique (1 1,12). In brief, 
pancreas was retrogradely filled with 3 ml of Hank’s Balanced Salt Solution 
(Sigma Chemical Co., St. Louis, U.S.A.), supplemented with 0.3 mg/ml of Colla- 
genase P (Boehringer Mannheim Gmbh, Germany). The pancreas was subsequently 
removed and incubated for 20 min at 37°C. After rinsing, the islets were hand- 
picked under a stereomicroscope and incubated overnight in RPMI 1640 medium. 
The islets were then washed three times and preincubated for 30 min at 37°C in a 
modified Krebs-Ringer bicarbonate medium, consisting of (in mmol/l): 114 NaCl, 



















































GLP-1, 2,5-AM AND INSULIN SECRETION 587 
glucose in 95% humified air/5% C02 athmosphere. The islets were then transferred 
to new chambers, and single islets were incubated individually in 0.1 ml of the 
Krebs-Ringer bicarbonate medium for 60 min at 37OC in an athmosphere of 95% 
air/5% COZ in the presence of 3 .3  or 8.3 mmovl glucose and/or 1.5, 7.5, 15 or 75 
mmol/l2,5-AM according to the respective protocols. After the 60 min incubation, 
aliquots of the medium (2x25 pl) were removed for insulin immunoassay. 
Analyses. 
The concentration of insulin in plasma and medium was determined by radioim- 
munoassay using guinea pig anti porcine insulin (Linco Research, St Louis, Mo, 
USA), I-labelled rat insulin (NOVO Nordic, Bagsvaerd, Denmark) and, as 
standard, rat insulin (Linco). The antigen-antibody complex was dissociated by the 
double antibody technique (13). Plasma glucose levels were determined with the 
glucose oxidase technique. Tissue glycogen content was performed in homoge- 
nized tissue as analysis of glucose after glycogen breakdown (14). 
125 
Statistics. 
Values are expressed as mean f SEM. The statistical comparisons were per- 
formed using two-way analysis of variance with the Neumann-Keul post hoc test. 
A probability level of random difference of P<0.05 was considered significant. 
RESULTS 
Studies in viva 
The intravenous injection of GLP-1 at 32 nmoykg was followed by a reduction 



















































588 AH&N ET AL. 
O L  I 1 I 1 1  I I 1 
0 5 10 15 20  25 30 35 
Time (minutes) 
FIGURE 1 
Plasma glucose levels before and after the intravenous injection of GLP-1 (32 
nmol/kg; 0-0), 2,5-AM (0.5 p m o y k g ; w  ), GLP-1 in combination with 2,5- 
AM (rc-r ), or in controls injected with saline (0-0). MeanskSEM are shown. 
There were 12 animals in each group. 
Similarly, 2,5-AM at 0.5 pmoykg reduced plasma glucose levels (Fig.1). When 
combined, GLP- 1 and 2,5-AM induced additive hypoglycemic responses. Plasma 
insulin levels were increased by GLP-1 at 5 min after injection (Table I) whereas at 
25 min after injection, plasma insulin levels after GLP-1 were not different from 
that in the controls. 2,5-AM abolished the GLP-l-induced increase in plasma 
insulin levels. Furthermore, at 30 min after intravenous injection, GLP-1 had not 
affected the glycogen content neither in the liver (31.1k1.6 mg/g tissue in controls; 
n=12, versus 29.8f1.8 mg/g tissue after GLP-1; n=lO) nor in the gastrocnemic 




















































GLP-1, 2.5-AM AND INSULIN SECRETION 589 
5 min 
Table 1 
Plasma insulin levels at 5 and 25 min after the intravenous injection of saline, GLP- 
25 min 
1, 2,5-M or GLP-1 together with 2,5-AM. MeansfSEM are shown. There were 12 
animals in each group. Asterisks indicate the probability level of random difference 




GLP-1 (32 mol/kg) 
2,5-AM (0.5 pmolkg) 
GLP-1 + 2,5-Ah4 
342k42 I 3 1 2 3 6  
I 
693 +68 * * I 3 18*40 
I I 
401k43 I 296*3 1 1 
Studies in vitro. 
When isolated mouse islets were incubated for 60 min, 2,5-AM at 75 mmovl 
inhibited glucose-(8.3 mmoV1)-stimulated insulin secretion. Thus, at 8.3 mmoVl 
glucose, the medium insulin secretion was 7 568+567 pmoVl (n=24 batch incuba- 
tions performed at 3 occassions) and this figure was reduced to 5 288+861 pmoVl 
by 2,5-AM at 75 mmoVl (P<0.,05; n=24). In contrast, at lower doses, 2,5-Ah4 did 
not significantly affect glucose-stimulated insulin secretion. 
DISCUSSION 
In liver cells, the p-D-fructose analogue, 2,5-AM, is phosphorylated by fructo- 
kinase to 2,5-AM- 1 -phosphate which is subsequently phosphorylated by phos- 
phofructokinase to 2,5-AM-2,6-biphosphate ( 1  5 ) .  This compound is not fkrther 
metabolized but is instead accumulated inside the cells in which it inhibits both glu- 
coneogenesis and glycogenolysis (10,15-17). Furthermore, due to its rapid phos- 



















































590 A H ~ N  ET AL. 
evolves that reduces the cellular content of ATP (1 9). Previously, these actions of 
2,S-AM have been shown to result in hypoglycemia when administered both in 
normal and diabetic mice and rats (10,20). We confirm in this study that 2,5-AM 
reduces plasma glucose levels in non-fasted normal mice. 
In this study, we also demonstrate that 2,5-AM inhibits insulin secretion, both 
under in vivo conditions following induction of insulin secretion by GLP-1 and 
under in vitro conditions since glucose-stimulated insulin secretion from isolated 
islets was also inhibited by the drug. The inhibitory action of 2,5-AM on insulin 
secretion in vivo is most likely exerted through a direct B cell action and not indi- 
rectly through a hypoglycemic action, since it was seen already at 5 min after its 
administration, whereas the glucose lowering action was seen first after 25 min. On 
the other hand, the dose level of 2,5-AM required to inhibit insulin secretion in 
vitro was higher than in vivo, which could indicate partial involvement of indirect 
mechanisms. The mechanisms underlying the inhibition by 2,5-AM of insulin se- 
cretion remain to be studied. It may be suggested that the inhibition is caused by 
depletion of B cell ATP, in analogy with the action of 2,5-AM in hepatocytes (19), 
provided that 2,5-AM undergoes a similar metabolism in the islet B cells as in 
hepatocytes. 
GLP-I has previously been shown to stimulate insulin secretion and to enhance 
the glucose elimination in nomal mice (3,8,9). In this study, we show that GLP-1, 
besides increasing plasma insulin levels, also lowers the plasma glucose to levels 
below those seen normally in normal mice, an effect that is seen at 15 min after its 
intravenous administration. Furthermore, when combined with 2,5-AM, GLP- 1 still 
lowered the glucose levels resulting in an additive hypoglycemic response of these 
two substances. Since 2,5-AM abolished the GLP-1-induced insulin secretion, it 
may be suggested that the glucose-lowering action of GLP-I under these condi- 



















































GLP-1, 2,5-AM AND INSULIN SECRETION 59 1 
action. Furthermore, since at the same time, 2,5-AM inhibits hepatic glu- 
coneogenesis and glycogenolysis (1 5-1 7), it seems reasonable to assume that the 
glucose lowering action of GLP-1 is not only insulin-independent but also inde- 
pendent of gluconeogenesis and glycogenolysis in the liver. Such a mechanism is 
corroborated by direct studies on possible actions of GLP-I on liver knction, 
demonstrating in this study that the peptide does not affect the liver glycogen con- 
tent and in other studies showing no effects by the peptide on the production of 
cyclic AMP (2 1) or glycogenolysis (22). In contrast, a stimulatory action of GLP- 1 
on liver glycogenesis has recently been demonstrated in isolated rat hepatocytes, 
which was suggested to underlie the glucose lowering action of the peptide (23). 
On the other hand, a study in humans has shown that GLP-I increases the insulin- 
independent peripheral glucose uptake (24), which suggests a peripheral, but in- 
sulin-independent, site of action. Our present study in normal mice therefore sup- 
ports this suggestion. The exact mechanism underlying the hypoglycemic action of 
GLP- 1 still remains intriguing, however, although stimulation of peripheral glucose 
uptake, for example in muscles, is at present the most likely explanation. In this 
context, it is of interest that a recent study has demonstrated that GLP-1 binds to 
skeletal muscles (25). 
In conclusion, this study has shown 1)that the fiuctose analogue, 2,5-anhydro- 
D-mannitol inhibits insulin secretion both in vivo and in vitro, 2)that GLP-I may 
reduce plasma glucose levels also to levels below the basal levels, and 3)that the 
glucose lowering action of GLP-1 seems to be mediated by an insulin-independent 
and probably also a liver-independent action. 
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